Thiadiazole derivatives: Highly potent and selective inhibitors of human immunodeficiency virus type 1 (HIV-1) replications in vitro

Microbiology and Immunology

Volumn 41, Issue 4, 1997, Pages 301-308

  Fujiwara, Masatoshi ^a   Ijichi, Katsushi ^a   Hanasaki, Yasuaki ^b   Ide, Teruhiko ^b   Katsuura, Kimio ^b   Takayama, Hiromitsu ^c   Aimi, Norio ^c   Shigeta, Shiro ^d   Konno, Kenji ^a   Yokota, Tomoyuki ^a   Baba, Masanori ^e  

^a Rational Drug Design Laboratories   (Japan)

^b TOSOH CORPORATION   (Japan)

^c CHIBA UNIVERSITY   (Japan)

^d FUKUSHIMA MEDICAL UNIVERSITY   (Japan)

^e KAGOSHIMA UNIVERSITY   (Japan)

Author keywords

Anti HIV 1 activity; Nonnucleoside reverse transcriptase inhibitor; Thiadiazole derivatives

Indexed keywords

A 75925; LOVIRIDE; RD 42024; RD 42217; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBIOTIC RESISTANCE; ANTIVIRAL ACTIVITY; ARTICLE; DRUG POTENTIATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOPHILICITY; PROTEIN BINDING; VIRUS INHIBITION;

HTLV; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0030976265     PISSN: 03855600     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1348-0421.1997.tb01205.x     Document Type: Article

References (21)

1. Baba, M., De Clercq, E., Tanaka, H., Ubasawa, M., Takashima, H., Sekiya, K., Nitta, I., Umezu, K., Nakashima, H., Mori, S., Shigeta, S., Walker, R.T., and Miyasaka, T. 1991. Potent and selective inhibitor of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 88: 2356-2360.
2. Baba, M., Yuasa, S., Niwa, T., Yamamoto, M., Yabuuchi, S., Takashima, H., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R.T., Balzarini, J., De Clercq, E., and Shigeta, S. 1993. Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio) thymin (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochem. Pharmacol. 45: 2507-2512.
3. Baba, M., Shigeta, S., Yuasa, S., Takashima, H., Sekiya, K., Ubasawa, M., Tanaka, H., Miyasaka, T., Walker, R.T., and De Clercq, E. 1994. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrob. Agents Chemother. 38: 688-692.
4. Balzarini, J., Karlsson, A., Pérez-pérez, M.-J., Camarasa, M.-J., and De Clercq, E. 1993. Knocking-out concentrations of HIV-1-specific inhibitors completely suppress HIV-1 infection and prevent the emergence of drug-resistant virus. Virology 196: 576-585.
5. Cheeseman, S.H., Havlir, D., McLaughlin, M.M., Greenough, T.C., Sullivan, J.L., Hall, D., Hattox, S.E., Spector, S.A., Stein, D.S., Myers, M., and Richman, D.D. 1995. Phase I/II evaluation of nevirapine alone and in combination with zidovudine for infection with human immunodeficiency virus. J. Acquir. Immun. Defic. Syndr. Hum. Retrovir. 8: 141-151.
6. 50, synergism, antagonism, low-dose risk, receptor-ligand binding and enzyme kinetics, p. 19-32. In A computer software for IBM-PC and manual, Elsevier-Biosoft, Cambridge.
7. Chou, T.-C., and Talalay, P. 1984. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Advancement Enzyme Regulation 22: 27-55.
8. Davey, J.-R.T., Chain, D.G., Reed, G.F., Freimuth, W.W., Herpin, B.R., Metcalf, J.A., Eastman, P.S., Falloon, J., Kovacs, J.A., Polis, M.A., Walker, R.E., Hasur, H., Boyle, J., Coleman, S., Cox, S.R., Wathen, L., Daenzer, C.L., and Lane, H.C. 1996. Randomized, controlled phase I/II trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrob. Agents Chemother. 40: 1657-1664.
9. Freimuth, B., Davey, R., Batts, D., Lane, C., Cox, S., Wathen, L., Peel, B., Daenzer, C., Morse, G., Chaitt, D., and Herpin, B. 1994. Phase II clinical trials of delavirdine mesylate combination therapy. Abst. 512B, p59, 10th Internatl. Conf. AIDS.
10. Hanasaki, Y., Watanabe, H., Katsuura, K., Takayama, H., Shirakawa, S., Yamaguchi, K., Sakai, S., Ijichi, K., Fujiwara, M., Konno, K., Yokota, T., Shigeta, S., and Baba, M. 1995. Thiadiazole derivatives: highly potent and specific HIV-1 reverse transcriptase inhibitors. J. Med. Chem. 38: 2038-2040.
11. Havlir, D., Cheeseman, S.H., McLaughlin, M., Murphy, R., Erice, A., Spector, S.A., Greenough, T.C., Sullivan, J.L., Hall, D., Myers, M., Lamson, M., and Richman, D.D. 1995. High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. J. Infect. Dis. 171: 537-545.
12. Ho, D.D., Neumann, A.U., Perelson, A.S., Chen, W., Leonard, J.M., and Markowitz, M. 1995. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 373: 123-126.
13. Ijichi, K., Fujiwara, M., Hanasaki, Y., Watanabe, H., Katsuura, K., Takayama, H., Shirakawa, S., Sakai, S., Shigeta, S., Konno, K., Yokota, T., and Baba, M. 1995. Potent and specific inhibition of human immunodeficiency virus type 1 replication by 4-(2,6-dichlorophenyl)-1,2,5-thiadiazol-3-yl N,N-dialkylcarbamate derivatives. Antimicrob. Agents Chemother. 39: 2337-2340.
14. Larder, B.A., Darby, G., and Rhichman, D.D. 1989. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 243: 1731-1734.
15. McCall, J.M. 1975. Liquid-liquid partition coefficients by high pressure liquid chromatography. J. Med. Chem. 18: 549-552.
16. Pauwels, R., Balzarini, J., Baba, M., Snoeck, R., Schols, D., Herdwijn, P., Desmyer, J., and De Clercq, E. 1988. Rapid and automated tetrazolium-based colorimetric assay for the detection of anti-HIV compounds. J. Virol. Methods 20: 309-321.
17. Pauwels, R., Andries, K., Desmyler, J., Schols, D., Kukla, M.J., Breslin, H.J., Raeymaeckers, A., Gelder, J.V., Woestenborghs, R., Heykants, J., Schellekens, K., Janssen, M.A.C., De Clercq, E., and Janssen, P.A.J. 1990. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives. Nature 343: 470-474.
18. Seki, M., Sadakata, Y., Yuasa, S., and Baba, M. 1995. Isolation and characterization of human immunodeficiency virus type-1 mutants resistant to the non-nucleoside reverse transcriptase inhibitor MKC-442. Antiviral Chem. Chemother. 6: 73-79.
19. Staszewski, S., Miller, V., Kober, A., Colebunders, R., Vandercam, B., Delescluse, J., Clumeck, N., Wanzeele, F.V., De Brabander, M., De Cree, J., Moeremans, M., Andries, K., Boucher, C., Stoffels, P., Janssen, P.A.J., and members of the Loviride Collaborative Study Group. 1996. Evaluation of the efficacy and tolerance of R018893, R089439 (loviride) and placebo in asymptomatic HIV-1-infected patients. Antiviral Ther. 1: 42-50.
20. Staszewski, S., Miller, V., Rehmet, S., Stark, T., De Cree, J., De Brabander, M., Peeters, M., Andries, K., Moeremans, M., De Raeymaeker, M., Pearce, G., Van Den Broeck, R., Verbiest, W., and Stoffels, P. 1996. Virological and immunological analysis of a triple combination pilot study with loviride, lamivudine and zidovudine in HIV-1-infected patients. AIDS 10: F1-F7.
21. Wei, X., Ghosh, S.K., Taylor, M.E., Johnson, V.A., Emini, E.A., Deutsch, P., Lifson, J.D., Bonhoeffer, S., Nowak, M.A., Haha, B.H., Saag, M.S., and Shaw, G.M. 1995. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 373: 117-122.